REFERENCES

1. Miller E, Dy I, Herzog T. Leptomeningeal carcinomatosis from ovarian cancer. Med Oncol 2012;29:2010-5.

2. Orphanos G, Ardavanis A. Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum. Clin Exp Metastasis 2010;27:19-23.

3. Dalhaug A, Haukland E, Nieder C. Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report). World J Surg Oncol 2010;8:36.

4. Theodore WH, Gendelman S. Meningeal carcinomatosis. Arch Neurol 1981;38:696-9.

5. Yap HY, Yap BS, Tashima CK, Distefano A, Blumenschein GR. Meningeal carcinomatosis in breast cancer. Cancer 1978;42:283-6.

6. Lee JL, Kang YK, Kim TW, Chang HM, Lee GW, Ryu MH, Kim E, Oh SJ, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Lee JS, Kim WK, Kim SH. Leptomeningeal carcinomatosis in gastric cancer. J Neurooncol 2004;66:167-74.

7. Nakagawa H, Murasawa A, Kubo S, Nakajima S, Nakajima Y, Izumoto S, Hayakawa T. Diagnosis and treatment of patients with meningeal carcinomatosis. J Neurooncol 1992;13:81-9.

8. Boogerd W, Vroom TM, van Heerde P, Brutel De L a Riviere G, Peterse JL, van der Sande JJ. CSF cytology versus immunocytochemistry in meningeal carcinomatosis. J Neurol Neurosurg Psychiatry 1988;51:142-5.

9. Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 2010;11:871-9.

10. Kaplan JG, DeSouza TG, Farkash A, Shafran B, Pack D, Rehman F, Fuks J, Portenoy R. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990;9:225-9.

11. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759-72.

12. Lampkin BC, Higgins GR, Hammond D. Absence of neurotoxicity following massive intrathecal administration of methotrexate. Case report. Cancer 1967;20:1780-1.

13. Tomita N, Takasaki H, Ishiyama Y, Kishimoto K, Ishibashi D, Koyama S, Ishii Y, Takahashi H, Numata A, Watanabe R, Tachibana T, Ohshima R, Hagihara M, Hashimoto C, Takemura S, Taguchi J, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 2015;56:725-9.

14. Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol 2013;8:1069-74.

15. Jo JC, Kang MJ, Kim JE, Ahn JH, Jung KH, Gong G, Kim HH, Ahn SD, Kim SS, Son BH, Ahn SH, Kim SB. Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience. Cancer Chemother Pharmacol 2013;72:201-7.

16. Marjanovic S, Mijuskovic Z, Stamatovic D, Madjaru L, Ralic T, Trimcev J, Stojanovic J, Radovic V, 2nd. Multiple myeloma invasion of the central nervous system. Vojnosanit Pregl 2012;69:209-13.

17. Tomita H, Yasui H, Boku N, Nakasu Y, Mitsuya K, Onozawa Y, Fukutomi A, Yamazaki K, Machida N, Taku K, Todaka A, Taniguchi H, Tsushima T. Leptomeningeal carcinomatosis associated with gastric cancer. Int J Clin Oncol 2012;17:361-6.

18. Minchom A, Chan S, Melia W, Shah R. An unusual case of pancreatic cancer with leptomeningeal infiltration. J Gastrointest Cancer 2010;41:107-9.

19. Varyani N, Thukral A, Garg S, Gupta KK, Tandon R, Tripathi K. Atypical neurofibroma and osteosclerotic metastasis. Case Rep Oncol Med 2012;2012:301437.

20. Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, Kesari S. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol 2014;119:361-8.

21. Patel A, Ayto R, MacDonald DH. Posterior reversible encephalopathy after intrathecal methotrexate therapy in diffuse large B-cell lymphoma. Br J Haematol 2013;161:607.

22. Back EH. Death after intrathecal methotrexate. Lancet 1969;2:1005.

23. Herrlinger U, Wiendl H, Renninger M, Forschler H, Dichgans J, Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 2004;91:219-24.

24. Pace A, Fabi A. Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol 2006;60:194-200.

25. Mason WP, Yeh SD, DeAngelis LM. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1998;50:438-44.

26. Tay AS, Liu EH, Lee TL, Miyazaki S, Nishimura W, Minami T, Chan YH, Low CM, Tachibana S. Cerebrospinal fluid of postherpetic neuralgia patients induced interleukin-6 release in human glial cell-line T98G. Neurochem Int 2013;63:517-21.

27. Valentin A, Troppan K, Pfeilstocker M, Nosslinger T, Linkesch W, Neumeister P. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia. Leuk Lymphoma 2014;55:1739-42.

28. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, Lafollette S, Schumann GB, Cole BF, Howell SB. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5:3394-402.

29. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol 2010;136:1729-35.

30. Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 2013;4:S265-88.